BioAtla, Inc.
BCAB- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001826892
No open-market purchases or sales by BioAtla, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $1.22M in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding BioAtla, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 43 | 39 | −4 |
| Shares | 13.7M | 13.2M | −538.6K (−3.9%) |
| Value | $4.77M | $5.21M | +$447.2K (+9.4%) |
New holders (5)
Institutions that held BioAtla, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| ADAR1 Capital Management, LLC | 170,506 | $67.5K | 0.01% |
| Alpha Cubed Investments, LLC | 41,144 | $16.3K | 0.00% |
| Tower Research Capital LLC (TRC) | 23,316 | $9.23K | 0.00% |
| HRT Financial LP | 20,740 | $8.00K | 0.00% |
| Advisor Group Holdings, Inc. | 500 | $195 | 0.00% |
Sold out (9)
Institutions that held BioAtla, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Squarepoint Ops LLC | 260,247 | $90.3K |
| Gsa Capital Partners LLP | 233,156 | $81.0K |
| Millennium Management LLC | 116,661 | $40.5K |
| Woodline Partners LP | 76,324 | $26.5K |
| R Squared Ltd | 11,710 | $4.06K |
| Flaharty Asset Management, LLC | 4,150 | $1.44K |
| Federated Hermes, Inc. | 2,027 | $703 |
| Barclays PLC | 6 | $2 |
| Royal Bank of Canada | 878 | $0 |